Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
National Heart, Lung, and Blood Institute (NHLBI)
Study Description: This protocol will collect information on frequency and severity of COVID infection for patients with rare diseases and community controls. Study Objectives: Primary Objective: To quantify the frequency and severity of COVID infection in patients with rare and common diseases, looking for conditions that increase risk of severe outcomes. Secondary Objective: To identify gene-, tissue- or sociodemographic level features that increase risk of severe COVID outcomes that may inform future genetic modifier studies. Tertiary Objective (exploratory): To investigate the role of pre- existing disease- or socioeconomic- factors that contribute to COVID- related stress and to evaluate whether individuals with the conditions studied experience more extreme symptoms around the time of COVID vaccine. Endpoints: Primary Endpoint: Frequency of severe infection (hospitalization +/- ICU stay and/or COVID-related death) secondary to COVID in patients with a shared disease designation. Secondary Endpoint: Frequency of severe infection (hospitalization +/- ICU stay and/or COVID-related death) secondary to COVID in patients with shared organ system involvement, secondary comorbidities, or sociodemographic differences. AND Frequency of any infection or symptoms (including long haul symptoms) secondary to COVID in study patients as grouped by genetic diagnosis, organ system involvement, secondary comorbidities, or sociodemographic features. Tertiary Endpoints (exploratory): Frequency and degree of COVID related stress based on pre-existing disease-, organ system-, or socioeconomic- factors and frequency of extreme symptoms following one of the COVID vaccines based on pre-existing disease-organ system-, or socioeconomic- factors. Study Population: The study will include people greater than 1 month old, with and without rare disease. Some members of the study population have cognitive impairment on the basis of their rare disease. Description of Sites/Facilities Enrolling Participants: All consent and study procedures/questionnaire will be performed online. Study Duration: The study will enroll for up to 13 months. Participant Duration: After consent, participants (or their legal authorized representative) will be asked to fill out an online questionnaire that should take \<30 minutes. We may re-send the survey to the participants in 6 - 12 months. Filling out the second round questionnaire is preferred but not required. New enrollees at the time the 2nd questionnaire is sent will fill out the questionnaire once at Time 2. If a signal for increased symptoms is identified in one or more studied groups, individuals from that group may be re-contacted with additional questions or request for medical records within the 13 month window. Participants will be consented for re-contact.
Age
0–any
Sex
ALL
Healthy volunteers
Not accepted
